Literature DB >> 26718829

Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Maarten E A Reith1,2, Aloke K Dutta3, Dana E Selley4, Juan Zhen1, Tamara Antonio1, Joanna C Jacob4, David K Grandy5.   

Abstract

In elucidating the role of pharmacodynamic efficacy at D3 receptors in therapeutic effectiveness of dopamine receptor agonists, the influence of study system must be understood. Here two compounds with D3 over D2 selectivity developed in our earlier work, D-264 and D-301, are compared in dopamine receptor-mediated G-protein activation in striatal regions of wild-type and D2 receptor knockout mice and in CHO cells expressing D2 or D3 receptors. In caudate-putamen of D2 knockout mice, D-301 was ~3-fold more efficacious than D-264 in activating G-proteins as assessed by [(35)S]GTPγS binding; in nucleus accumbens, D-301 stimulated G-protein activation whereas D-264 did not. In contrast, the two ligands exerted similar efficacy in both regions of wild-type mice, suggesting both ligands activate D2 receptors with similar efficacy. In D2 and D3 receptor-expressing CHO cells, D-264 and D-301 appeared to act in the [(35)S]GTPγS assay as full agonists because they produced maximal stimulation equal to dopamine. Competition for [(3)H]spiperone binding was then performed to determine Ki/EC50 ratios as an index of receptor reserve for each ligand. Action of D-301, but not D-264, showed receptor reserve in D3 but not in D2 receptor-expressing cells, whereas dopamine showed receptor reserve in both cell lines. Gαo1 is highly expressed in brain and is important in D2-like receptor-G protein coupling. Transfection of Gαo1 in D3- but not D2-expressing CHO cells led to receptor reserve for D-264 without altering receptor expression levels. D-301 and dopamine exhibited receptor reserve in D3-expressing cells both with and without transfection of Gαo1. Altogether, these results indicate that D-301 has greater intrinsic efficacy to activate D3 receptors than D-264, whereas the two compounds act on D2 receptors with similar intrinsic efficacy. These findings also suggest caution in interpreting Emax values from functional assays in receptor-transfected cell models without accounting for receptor reserve.

Entities:  

Keywords:  D2; D3; Dopamine receptors; G protein; Gαo1; Intrinsic efficacy; Rat tissue; [35S]GTPγS binding assay

Mesh:

Substances:

Year:  2015        PMID: 26718829      PMCID: PMC4775387          DOI: 10.1007/s11064-015-1808-6

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  56 in total

1.  Coupling of dopamine receptors to G proteins: studies with chimeric D2/D3 dopamine receptors.

Authors:  Tal Ilani; C Simone Fishburn; Berta Levavi-Sivan; Shari Carmon; Lily Raveh; Sara Fuchs
Journal:  Cell Mol Neurobiol       Date:  2002-02       Impact factor: 5.046

2.  Relationship between the G protein signaling and homologous desensitization of G protein-coupled receptors.

Authors:  Larry S Barak; Jacqueline Gilchrist; Jeffrey M Becker; Kyeong-Man Kim
Journal:  Biochem Biophys Res Commun       Date:  2006-01-13       Impact factor: 3.575

3.  G-protein sensitivity of ligand binding to human dopamine D(2) and D(3) receptors expressed in Escherichia coli: clues for a constrained D(3) receptor structure.

Authors:  J F Vanhauwe; K Josson; W H Luyten; A J Driessen; J E Leysen
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

4.  Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.

Authors:  Sanjib Gogoi; Tamara Antonio; Subramanian Rajagopalan; Maarten Reith; Julie Andersen; Aloke K Dutta
Journal:  ChemMedChem       Date:  2011-05-12       Impact factor: 3.466

5.  Comparison of the ligand binding and signaling properties of human dopamine D(2) and D(3) receptors in Chinese hamster ovary cells.

Authors:  J F Vanhauwe; N Fraeyman; B J Francken; W H Luyten; J E Leysen
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

6.  Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907.

Authors:  H Hall; C Halldin; D Dijkstra; H Wikström; L D Wise; T A Pugsley; P Sokoloff; S Pauli; L Farde; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1996-12       Impact factor: 4.530

Review 7.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Authors:  P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-02       Impact factor: 4.388

8.  Relationship between receptor occupancy and response at striatal dopamine autoreceptors.

Authors:  E Meller; K Bohmaker; Y Namba; A J Friedhoff; M Goldstein
Journal:  Mol Pharmacol       Date:  1987-06       Impact factor: 4.436

9.  Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation.

Authors:  Chiara Bianca Maria Platania; Salvatore Salomone; Gian Marco Leggio; Filippo Drago; Claudio Bucolo
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

Review 10.  The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.

Authors:  Ralf Brisch; Arthur Saniotis; Rainer Wolf; Hendrik Bielau; Hans-Gert Bernstein; Johann Steiner; Bernhard Bogerts; Katharina Braun; Anna Katharina Braun; Zbigniew Jankowski; Jaliya Kumaratilake; Jaliya Kumaritlake; Maciej Henneberg; Tomasz Gos
Journal:  Front Psychiatry       Date:  2014-05-19       Impact factor: 4.157

View more
  2 in total

Review 1.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

2.  Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.

Authors:  Amy E Moritz; R Benjamin Free; Warren S Weiner; Emmanuel O Akano; Disha Gandhi; Ara Abramyan; Thomas M Keck; Marc Ferrer; Xin Hu; Noel Southall; Joseph Steiner; Jeffrey Aubé; Lei Shi; Kevin J Frankowski; David R Sibley
Journal:  J Med Chem       Date:  2020-05-12       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.